BPC-157: Preclinical Research Overview

What is BPC-157?

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a stable 15-amino-acid sequence (GEPPPGKPADDAGLV) derived from a protein found in gastric juice — studied in animal models for its association with tissue repair, angiogenesis and gastrointestinal protection. It is supplied strictly as a research reagent for in vitro use, not for human or veterinary consumption. (A peptide is simply a short chain of amino acids, the same building blocks that make up proteins.)

Unlike many peptides studied in the laboratory, BPC-157 is notable in the research literature for its stability — it remains intact in aqueous solution and in gastric environments under experimental conditions, which is one reason it has been used widely as a research reagent in tissue-response and cell-migration models.

Mechanisms Studied in Preclinical Research

Across in vitro and animal-model literature, several signalling pathways recur in connection with BPC-157. The following summarise reported research observations — not therapeutic effects.

Angiogenesis & the VEGFR2–eNOS–NO pathway

Cell-culture and rodent studies have examined BPC-157 in the context of angiogenesis (the formation of new blood vessels), reporting associations with VEGFR2 (vascular endothelial growth factor receptor 2) signalling and the eNOS/nitric-oxide axis in endothelial cells.[1]

Tendon & ligament fibroblasts

In vitro work using cultured tendon fibroblasts has reported effects on cell outgrowth, survival and migration, alongside changes in growth-hormone-receptor expression — commonly used markers in tissue-repair research models.[2]

Gastrointestinal mucosal integrity

Given its origin as a gastric-juice protein fragment, much early research examined BPC-157 in models of gastrointestinal mucosal integrity and the gut-brain axis under experimental injury conditions in animals.[3]

BPC-157 is frequently studied alongside TB-500 in tissue-repair models, where the two contribute complementary mechanisms — angiogenesis versus actin-driven cell migration. For a side-by-side breakdown, see BPC-157 vs TB-500.

Key Research Literature

BPC-157 has an extensive preclinical literature, much of it from the research groups of Sikiric and Seiwerth and collaborators. Selected representative work:

Summaries above are derived from publicly available peer-reviewed literature and describe research observations only. They are not claims of efficacy or safety in humans.

Handling in the Laboratory

Velox BPC-157 is supplied as lyophilised (freeze-dried) powder. For research use it is reconstituted with bacteriostatic water; our reconstitution calculator assists with concentration calculations.

• Lyophilised storage: −20°C, dry and dark.
• Reconstituted storage: 2–8°C; avoid freeze–thaw cycles.
• Verification: every batch is third-party HPLC-tested; batch documentation available on request.

References

1. Research on BPC-157 and VEGFR2/eNOS-NO angiogenic signalling — see PubMed.
2. Chang C-H, Tsai W-C, et al., J Appl Physiol, 2011 — tendon fibroblast outgrowth, survival and migration. PubMed.
3. Sikiric P, Seiwerth S, et al. — reviews of BPC-157 in gastrointestinal and gut-brain-axis research models. PubMed.

Frequently Asked Questions